Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun 18;10(6):e0129376.
doi: 10.1371/journal.pone.0129376. eCollection 2015.

The HIV Care Continuum: Changes over Time in Retention in Care and Viral Suppression

Baligh R Yehia  1 , Alisa J Stephens-Shields  2 , John A Fleishman  3 , Stephen A Berry  4 , Allison L Agwu  4 , Joshua P Metlay  5 , Richard D Moore  4 , W Christopher Mathews  6 , Ank Nijhawan  7 , Richard Rutstein  8 , Aditya H Gaur  9 , Kelly A Gebo  4 ; HIV Research Network
Collaborators, Affiliations

The HIV Care Continuum: Changes over Time in Retention in Care and Viral Suppression

Baligh R Yehia et al. PLoS One. .

Abstract

Background: The HIV care continuum (diagnosis, linkage to care, retention in care, receipt of antiretroviral therapy (ART), viral suppression) has been used to identify opportunities for improving the delivery of HIV care. Continuum steps are typically calculated in a conditional manner, with the number of persons completing the prior step serving as the base population for the next step. This approach may underestimate the prevalence of viral suppression by excluding patients who are suppressed but do not meet standard definitions of retention in care. Understanding how retention in care and viral suppression interact and change over time may improve our ability to intervene on these steps in the continuum.

Methods: We followed 17,140 patients at 11 U.S. HIV clinics between 2010-2012. For each calendar year, patients were classified into one of five categories: (1) retained/suppressed, (2) retained/not-suppressed, (3) not-retained/suppressed, (4) not-retained/not-suppressed, and (5) lost to follow-up (for calendar years 2011 and 2012 only). Retained individuals were those completing ≥ 2 HIV medical visits separated by ≥ 90 days in the year. Persons not retained completed ≥ 1 HIV medical visit during the year, but did not meet the retention definition. Persons lost to follow-up had no HIV medical visits in the year. HIV viral suppression was defined as HIV-1 RNA ≤ 200 copies/mL at the last measure in the year. Multinomial logistic regression was used to determine the probability of patients' transitioning between retention/suppression categories from 2010 to 2011 and 2010 to 2012, adjusting for age, sex, race/ethnicity, HIV risk factor, insurance status, CD4 count, and use of ART.

Results: Overall, 65.8% of patients were retained/suppressed, 17.4% retained/not-suppressed, 10.0% not-retained/suppressed, and 6.8% not-retained/not-suppressed in 2010. 59.5% of patients maintained the same status in 2011 (kappa=0.458) and 53.3% maintained the same status in 2012 (kappa=0.437).

Conclusions: Not counting patients not-retained/suppressed as virally suppressed, as is commonly done in the HIV care continuum, underestimated the proportion suppressed by 13%. Applying the care continuum in a longitudinal manner will enhance its utility.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have read the journal's policy and the authors of this manuscript have the following competing interests: BRY received investigator-initiated research support (to the University of Pennsylvania) and consulting fees from Gilead Sciences. SAB has been a consultant for Bristol-Myers Squibb. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

References

    1. Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, Gilson R, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS. 2013. March 27; 27(6):973–979. 10.1097/QAD.0b013e32835cae9c - DOI - PubMed
    1. Arribas JR, Eron J. Advances in antiretroviral therapy. Curr Opin HIV AIDS. July 2013;8(4):341–349. 10.1097/COH.0b013e328361fabd - DOI - PubMed
    1. Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV. BMJ Open. 2013;3(8). - PMC - PubMed
    1. Berry SA, Fleishman JA, Moore RD, Gebo KA. Trends in reasons for hospitalization in a multisite United States cohort of persons living with HIV, 2001–2008. J Acquir Immune Defic Syndr. 2012. April 1;59(4):368–375. 10.1097/QAI.0b013e318246b862 - DOI - PMC - PubMed
    1. Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS. 2010. November 27;24(18):2835–2840. 10.1097/QAD.0b013e328340a209 - DOI - PMC - PubMed

Publication types

Substances